Furazolidone in Peptic Ulcer

Zhao, Huaiyu; Li, Guozhen; Jundong, Guo; Zhi, Yi; Sun, Su-Wen; Li, Linsheng; Youmao, Duan; Fuzu, Yue

doi:10.1016/s0140-6736(85)90324-1

Cited by 10 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furazolidone, when used alone for treating peptic ulcer disease, can result in healing rates comparable to those attained by cimetidine with a much lower relapse rate 44 , . 45 The efficacy of furazolidone in the treatment of peptic ulcer disease is shown to be mainly due to it’s antibacterial activity against H. pylori 46 , . 47…”

Section: Discussionmentioning

confidence: 99%

Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate

Fakheri

Malekzadeh

Merat

et al. 2001

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Background: The eradication of Helicobacter pylori plays a pivotal role in the treatment of peptic ulcer disease. Metronidazole resistance, common in Iran, is claimed to be a major reason for the failure of metronidazole‐containing regimens. Both clarithromycin and furazolidone are potential alternatives for metronidazole. Aim: To assess and compare the effectiveness of clarithromycin‐ and furazolidone‐based regimens in eradicating H. pylori in a population with a high metronidazole resistance rate. Methods: Patients with proven duodenal ulcer and H. pylori infection were randomly assigned to one of two groups. The patients received 2 weeks of omeprazole 20 mg b.d., amoxicillin 1000 mg b.d, bismuth subcitrate 240 mg b.d. and either clarithromycin 500 mg b.d. (the OABC group) or furazolidone 200 mg b.d. (the OABF group). Results: A total of 118 patients were randomized, 55 in the OABC group and 63 in the OABF group. The intention‐to‐treat eradication rate was 84% and 85% for the OABF and OABC groups, respectively. The per protocol eradication rates were 90% for both groups. Conclusions: OABC and OABF are both effective in eradicating H. pylori in areas where metronidazole resistance is a problem. OABF is a good alternative in the face of growing resistance to clarithromycin in developed countries, and is attractive for developing countries where clarithromycin is not readily available.

show abstract

Section: Discussionmentioning

confidence: 99%

Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate

Fakheri

Malekzadeh

Merat

et al. 2001

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Furazolidone has been used as a treatment for acid peptic disease in China for more than 20 years; clinical experience with furazolidone alone in the treatment of peptic‐ulcer disease has shown that it can result in a healing rate comparable to that attained by cimetidine with a much lower relapse rate 25 , . 26 The mechanism of action of furazolidone in the treatment of peptic ulcer disease, which was previously thought to be at least partly due to monoamine oxidase inhibitory reaction of this drug, was later shown to be in most part due to antibacterial activity against H. pylori. 27 , 28…”

Section: Discussionmentioning

confidence: 99%

Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease

Malekzadeh

Ansari

Vahedi

et al. 2000

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Objective: Furazolidone, an old but cheap antibiotic, was shown to be a good alternative to metronidazole in triple therapy for Helicobacter pylori eradication in areas where metronidazole resistant bacteria are common, but randomized studies are lacking. Aim: A randomized controlled trial to determine the efficacy and safety of furazolidone compared to metronidazole in classic quadruple therapy for eradication of H. pylori infection in duodenal ulcer patients. Methods: Patients with endoscopically proven duodenal ulcer and positive urease test were randomized to receive ranitidine 300 mg, amoxycillin 1000 mg and bismuth subcitrate 240 mg b.d, with either furazolidone 200 mg b.d (RABF), or metronidazole 500 mg b.d. (RABM) for 2 weeks. Compliance and side‐effects were monitored and recorded by table diary. H. pylori eradication was assessed at least 4 weeks after the completion of therapy with 14C‐urea breath test. Results: A total of 106 patients were enrolled and 101 (59 male, 42 female, mean age=40 ± 11 years) completed the study. Endoscopic findings and demographic data were comparable in both groups. Intention‐to‐treat eradication rates were 75% and 55% (P=0.03) and per protocol eradication rates were 82 and 56% (P=0.006) in the RABF and RABM groups, respectively. Side‐effects were reported by 13 patients (27%) in the RABF group (one stopped treatment) compared to five patients (10%) in the RABM group (P=0.04). Conclusion: Quadruple therapy containing furazolidone, instead of metronidazole, results in a significantly higher H. pylori eradication rate in Iranian duodenal ulcer patients.

show abstract